Medical/Pharmaceuticals
Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC
SUZHOU, China, Jan. 12, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the TST001 US P...
2022-01-12 15:15
4000
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease
* ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease * ABL301 uses ABL's Grabody-B platform technology to ef...
2022-01-12 07:59
4396
PostEra Closes $24M in New Financing to Advance Drug Discovery
BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of ...
2022-01-11 22:00
4173
Cambrex Celebrates its 40th Anniversary while Investing over $100 million in New Drug Substance Manufacturing Capacity
EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire/ -- Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to ...
2022-01-11 21:30
3545
Gift of Life Donor Program Breaks National Records in Saving Lives 705 Organ Donors, Leading to 1,732 Life-Saving Transplants
New CEO Richard Hasz Salutes Region – the Most Generous in the Nation for 14 Consecutive Years – and Team of "Heroes" for Extraordinary Commitment PHILADELPHIA, Jan. 11, 2022 /PRNewswire/ -- Gift of Life Donor Program once again leads the nation among all 57 U.S. organ procurement organizations (...
2022-01-11 21:05
4043
Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China
BEIJING and PRINCETON, N.J., Jan. 11, 2022 /PRNewswire/ -- Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their pa...
2022-01-11 21:00
4047
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study
BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...
2022-01-11 20:27
2433
China's 2021 U.S. Patent Grants Surged, Even as Total Patent Awards Trended Downward, According to Analysis by IFI CLAIMS
2021 Rankings Shed Light on Corporate R&D Priorities: Telemedicine, Supply Chain Efficiencies, E-Cigs and Artificial Intelligence Among Hottest Areas of Activity NEW HAVEN, Conn., Jan. 11, 2022 /PRNewswire/ -- Enhancements in telemedicine, more hardy grains to feed the world in a time of climate...
2022-01-11 18:00
2064
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...
2022-01-11 16:30
4601
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...
2022-01-11 15:15
3325
SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections
COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...
2022-01-11 14:29
1884
MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai's Guangdong Week
DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in theMiddle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion fromJanuary 11-13. The ...
2022-01-11 14:00
2768
Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy
2022-01-11 09:30
3317
Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod
* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...
2022-01-11 09:00
3262
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...
2022-01-11 08:30
4515
Dr. Ivan Puah Highlights The Significant Impact Of Covid That Changes Our Priority In Life
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- The current pandemic has raised more awareness of the importance of health and better care of oneself. Dr.Ivan Puah, Medical Director at Amaris B. Clinic shares how people's lifestyles and priorities have changed since Covid-19 started. 01. Losing we...
2022-01-11 06:44
2685
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmace...
2022-01-11 05:30
5188
The new symptoms of the COVID period that CDAHK doctors have uncovered
HONG KONG, Jan. 10, 2022 /PRNewswire/ -- As the COVID-19 Omicron variety continues to spread, chiropractors see a spike in neck pathology from work-from-home, remote learning during pandemic. For 30 years before the COVID-19 pandemic, the majority of chiropractic patients were suffering from bac...
2022-01-10 23:52
2699
New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation
PLYMOUTH MEETING, Pa., Jan. 10, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients®: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occurs after a donor stem cell or bone marrow (a.k.a. hematopo...
2022-01-10 21:37
2301
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines
2022-01-10 21:35
5391
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 312 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
23118
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
22091
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
11907